Cardiovascular System
Cardiovascular
High-yield cardiovascular physiology, pharmacology, and clinical management — extracted and organized from Divine Intervention episodes, optimized for USMLE Step 1–3 performance.
Physiology
Cardiac output, stroke volume, preload, and venous return form the conceptual spine of all cardiovascular questions. These episodes build the mechanical intuition — why blood pressure falls with inspiration, why nitrates kill RCA infarct patients, why AV fistulas cause high-output heart failure — that lets you reason through unfamiliar vignettes rather than guess.
EP464
Cardiovascular Parameters, Part 1
- Cardiac Output = HR × SV; stroke volume determined by preload, afterload, and contractility — all three are independently testable
- Systolic BP = initial aortic pressure after LV ejection; diastolic BP = primary determinant is SVR (TPR) — not heart rate
- Pulse pressure widens in exercise: SBP rises (more SV) while DBP falls (ADP/AMP → vasodilation → ↓SVR)
- Dobutamine → hypokalemia: β1 agonism at JG cells → ↑renin → ↑angiotensin II → ↑aldosterone → ↑K⁺ excretion
- Stable angina workup: if symptoms persist despite supervised walking + cilostazol → next step is stress testing or coronary angiography
Cardiovascular Parameters — Core Equations
| Parameter | Formula / Determinant | Clinical Note |
|---|---|---|
| Cardiac Output | HR × Stroke Volume | Normal ~5 L/min |
| Stroke Volume | EDV − ESV | Preload ↑ → SV ↑ (Frank-Starling) |
| Systolic BP | Initial aortic pressure after ejection | ↑ with ↑SV or ↑CO |
| Diastolic BP | Primary: SVR (TPR) | ↓SVR → ↓DBP even with ↑HR |
| Pulse Pressure | SBP − DBP | Widened: AR, exercise, septic shock, myorinone |
| MAP | DBP + 1/3(PP) | Target >65 in shock resuscitation |
Exercise Physiology — Why Diastolic BP Falls
- ATP → ADP → AMP during muscle contraction; these metabolites are potent vasodilators that reduce SVR
- SVR falls → DBP falls, even as SBP rises → net widening of pulse pressure with exercise
- This is the only physiologic state where SBP and DBP move in opposite directions
Dobutamine Integration Chain
- Dobutamine (β1 agonist) → stimulates JG cells → ↑renin → ↑angiotensin I/II → ↑aldosterone
- Aldosterone → ↑K⁺ excretion → hypokalemia
- NBME may give an "arrow" question: dobutamine + potassium → potassium goes DOWN
Key Integration
Primary determinant of diastolic BP = SVR. When SVR goes down (vasodilators, sepsis, exercise), DBP falls regardless of heart rate. This explains why vasodilators cause reflex tachycardia without raising DBP.
EP465
Cardiovascular Parameters 2: Venous Return & Preload
- Preload = EDV (end-diastolic volume); primary driver is venous return — more blood returning → more preload → more CO (Frank-Starling)
- Standing → supine: ↑venous return → ↑preload → ↑murmur intensity for most valvular lesions; exception: MVP and HOCM — preload ↑ transiently fixes the problem → murmur decreases
- RCA infarct + nitrates = cardiogenic collapse: nitrates are venodilators → ↓venous return → ↓preload → RV-dependent CO crashes
- Valsalva maneuver: blowing against closed glottis → ↑intrathoracic pressure → compresses SVC/IVC → ↓venous return → most murmurs soften (MVP and HOCM get louder)
- AV fistula → high-output heart failure: bypasses capillary bed → blood returns faster → ↑venous return → ↑CO chronically
- Pulsus paradoxus pathophysiology: inspiration → ↑RV volume → RV bulges into LV via IVS → ↓LV filling → ↓SBP >10 mmHg (cardiac tamponade, severe asthma)
Factors That Increase Venous Return (→ ↑Preload)
- Supine position (from standing): gravity no longer pools blood in legs
- Exercise: skeletal muscle contraction squeezes veins → ejects blood toward heart
- Inspiration: ↓intrathoracic pressure → heart becomes low-pressure system → pulls blood in
- IV fluids: ↑blood volume → ↑venous return (used in RCA infarct, hypovolemic shock)
- AV fistula: bypasses capillary transit time → blood returns faster chronically
Factors That Decrease Venous Return (→ ↓Preload)
- Standing: gravity pools blood in lower extremities
- Valsalva maneuver: ↑intrathoracic pressure compresses SVC/IVC
- Nitrates: venodilation → ↑venous capacitance → blood pools in veins, not heart
- Tension pneumothorax: air compresses SVC/IVC/heart → ↓venous return
- Hemorrhage / diuretics: ↓blood volume
- Varicose veins: incompetent valves → blood refluxes away from heart
Murmur Changes with Preload — The Rules
| Maneuver | Preload Effect | Most Murmurs | MVP & HOCM |
|---|---|---|---|
| Standing | ↓ | ↓ intensity | ↑ intensity |
| Supine | ↑ | ↑ intensity | ↓ intensity |
| Valsalva (strain phase) | ↓ | ↓ intensity | ↑ intensity |
| Squatting | ↑ | ↑ intensity | ↓ intensity |
| Exercise | ↑ | ↑ most | variable |
High-Yield Trap: RCA Infarct + Nitrates
ST elevations in leads II, III, aVF = RCA infarct. RV is ischemic and preload-dependent. Give nitrates → venodilation → ↓preload → RV output crashes → cardiogenic shock. Instead: morphine for pain, small IV fluid bolus to maintain RV preload. This is one of the most commonly tested MI scenarios.
Pulsus Paradoxus — Mechanism
- Normal: inspiration → ↑RV filling → RV expands slightly into pericardium + IVS → LV gets slightly smaller → SBP drops <10 mmHg (physiologic)
- Cardiac tamponade: pericardium filled with fluid → RV cannot expand into pericardium → all expansion goes through IVS into LV → LV gets much smaller → SBP drops >10 mmHg
- Severe asthma: air trapping → ↑intrathoracic pressure → same IVS-bulging mechanism
- Kussmaul's sign (JVD with inspiration) = constrictive pericarditis: heart encased in calcium, cannot expand to accept increased venous return → JVs distend instead of collapsing
RR 108EP500
Cardiac Pressures, PCWP, and Obstruction Patterns
- Viral myocarditis (Coxsackie B): URI → HF symptoms + S3 → all cardiac pressures elevated (PCWP, CVP, hepatic venous pressure)
- Budd-Chiari syndrome (hepatic vein thrombosis): JVP normal, hepatic venous pressure ↑, cardiac pressures low/normal — obstruction is post-sinusoidal but pre-cardiac
- Pulmonary embolism: sudden JVD + hypoxia → right-sided pressures ↑, PCWP normal/low (no left heart involvement)
- Rule for "where is the obstruction?": everything upstream of blockage is elevated; everything downstream is low/normal
Cardiac Pressure Pattern by Diagnosis
| Condition | PCWP (LA) | CVP (RA) | Hepatic VP | JVP |
|---|---|---|---|---|
| Viral myocarditis / HFrEF | ↑↑ | ↑↑ | ↑ | ↑ |
| Pulmonary embolism | Normal/↓ | ↑↑ | Normal | ↑ |
| Budd-Chiari (hepatic vein thrombosis) | Normal/↓ | Normal/↓ | ↑↑ | Normal |
| Cardiogenic shock (acute MI) | ↑↑ | ↑ | ↑ | ↑ |
| Hypovolemic shock | ↓↓ | ↓↓ | ↓ | ↓ |
Logical Framework
Find the obstruction on the diagram. Everything upstream (before the block) = elevated pressure. Everything downstream (after the block) = low or normal pressure. Apply this to every cardiac pressure question.
Viral Myocarditis
- Classic: URI (rhinorrhea, cough) → 2 weeks later → bilateral leg edema, orthopnea, pulmonary crackles, S3
- S3 = code for systolic dysfunction / HFrEF on NBME exams
- Cause: Coxsackie B (most testable); biopsy shows lymphocytic infiltrate
- Treatment: standard HF therapy (no specific antiviral); most recover spontaneously
ACS & Ischemic Heart Disease
From unstable angina through STEMI to post-MI structural complications, this cluster covers the full ACS timeline. The unifying theme: match the acuity of the presentation to the acuity of the intervention. High-risk features (hemodynamic instability, mechanical complications, sustained arrhythmia) go straight to the cath lab; low-risk features go through stress testing first. Thrombosis management and MI pathological staging round out the picture.
EP477
The Clutch Acute Coronary Syndromes Podcast
- UA/NSTEMI management decision: high-risk features (hemodynamic instability, HF, sustained arrhythmia, mechanical complication, refractory pain) → immediate cath lab; low-risk → admit, stress test, then cath only if ischemia confirmed
- Universal UA/NSTEMI drugs: aspirin + clopidogrel (dual antiplatelet) + beta blocker + statin + nitrate + heparin — ALL patients regardless of cath vs. stress test path
- STEMI management: primary PCI is gold standard within 90 min; if PCI unavailable within 120 min → lytics (tPA); biomarkers: troponin first rises 3–6h, peaks 24h; CK-MB useful for re-infarction (returns to baseline faster)
- Biomarker timing: first 30 min of chest pain → ECG and serial troponins; troponin stays elevated 7–10 days; CK-MB normalizes by 48h (use for suspected reinfarction)
- Post-STEMI therapy: ASA + P2Y12 + beta blocker + statin + ACE inhibitor (especially if EF reduced) lifelong
ACS Classification
| Type | ECG | Troponin | Mechanism |
|---|---|---|---|
| Stable Angina | Normal at rest; ST depression on stress | Normal | Fixed stenosis, demand ischemia |
| Unstable Angina | ST depression / T-wave changes | Normal | Plaque rupture, no complete occlusion |
| NSTEMI | ST depression / T-wave changes | Elevated | Plaque rupture, partial occlusion |
| STEMI | ST elevation in territory; new LBBB | Elevated | Complete coronary occlusion |
UA/NSTEMI — Cath Lab vs. Medical Management
Go straight to cath if ANY high-risk feature present:
- Hemodynamic instability / cardiogenic shock
- New heart failure symptoms
- Sustained ventricular arrhythmia
- Mechanical complication (VSD, papillary rupture)
- Refractory chest pain despite maximal medical therapy
If none present: admit → stress test → cath only if significant ischemia on stress test.
High-Yield Trap: TIMI Score
Don't memorize every TIMI component — waste of time. Just know: TIMI 0–2 = low risk (stress test path); TIMI 3–7 = high risk (cath lab path). The factors themselves map to the "is this really bad?" intuition.
Coronary Artery Territories
| Artery | ECG Leads | Structure Supplied | Key Complication |
|---|---|---|---|
| LAD | V1–V4 | Anterior LV, anterior IVS | LV failure, anterior papillary rupture |
| RCA | II, III, aVF | RV, posterior LV, SA/AV node | Heart block, RV infarct |
| LCx | I, aVL, V5–V6 | Lateral LV | Posterior MI (reciprocal changes V1–V2) |
EP445
The Clutch MI Complications Podcast
- VSD post-MI: new holosystolic murmur at left lower sternal border, 3–5 days after MI, oxygen step-up from RA to RV on swan; treat with emergency surgery
- Papillary muscle rupture: new holosystolic murmur at apex (mitral regurgitation) with acute pulmonary edema; posterior papillary (single blood supply from RCA) > anterior (dual supply); peak day 3–5
- Ventricular free wall rupture: PEA (pulseless electrical activity) + sudden hemodynamic collapse + cardiac tamponade; day 3–7; most lethal MI complication
- Dressler syndrome: 2–6 weeks post-MI; pericarditis from autoimmune reaction (anti-heart antibodies); treat with aspirin/NSAIDs
- MI pathological staging: 0–24h = coagulation necrosis (dark); day 1–7 = neutrophil infiltration then macrophages (yellow); week 1–3 = fibroblasts, type I collagen; week 3+ = dense scar
MI Complications Timeline
| Timing | Complication | Mechanism | Key Clue |
|---|---|---|---|
| Hours 1–24 | Arrhythmia (VFib most lethal) | Ischemia → reentry | Leading cause of death in first 24h |
| Day 1–3 | Cardiogenic shock | Massive LV dysfunction | ↓BP, ↑PCWP, ↑JVD |
| Day 3–5 | VSD | Softening of IVS → rupture | New LLSB holosystolic murmur |
| Day 3–5 | Papillary muscle rupture | Ischemic necrosis of papillary | New apical holosystolic murmur + flash pulmonary edema |
| Day 3–7 | Free wall rupture | Macrophage digestion of myocardium | Sudden PEA + tamponade |
| Week 2–6 | LV aneurysm | Scar bulges outward; paradoxical motion | Persistent ST elevation >2 weeks |
| Week 2–6 | Dressler syndrome | Autoimmune pericarditis | Fever, pleuritic chest pain, ↑ESR post-MI |
MI Histopathology Staging (Step 1 Integration)
- 0–6 hours: normal histology (no changes visible under microscope yet)
- 6–24 hours: wavy fibers, coagulation necrosis begins; macroscopically dark
- 1–3 days: neutrophil infiltration (acute inflammation)
- 3–7 days: macrophages replace neutrophils (yellow appearance macroscopically from lipid-laden macrophages)
- 1–3 weeks: granulation tissue + fibroblasts → Type I collagen laid down
- >3 weeks: dense white scar (most vulnerable period for free wall rupture is day 3–7)
Papillary Muscle Anatomy — Why Posterior Ruptures More
Posterior papillary muscle = single blood supply from RCA only. Anterior papillary muscle = dual supply (LAD + LCx). Single-supply muscle is more vulnerable to ischemia → posterior papillary ruptures more frequently despite anterior MI being more common overall.
EP444
The Clutch Thromboses Podcast
- Virchow's triad: endothelial injury + hypercoagulability + stasis — any combination drives DVT/PE/arterial thrombosis
- Budd-Chiari syndrome (hepatic vein thrombosis): triad of RUQ pain + rapid-onset ascites + hepatomegaly; causes = PNH, polycythemia vera (JAK2 mutation), hypercoagulable states
- Portal vein thrombosis: cirrhosis + pancreatitis + hypercoagulable state → portal HTN without cardiac pressure elevation; distinguish from Budd-Chiari by location
- Polycythemia vera: JAK2 mutation → ↑viscosity → ↑thrombosis risk → Budd-Chiari; low EPO (negative feedback) is the distinguishing lab vs. secondary polycythemia
- Antiphospholipid antibody syndrome: recurrent arterial AND venous thromboses + recurrent fetal loss + ↑PTT (paradox: PTT elevated but thrombotic); treat with warfarin
Hypercoagulable States — NBME Favorites
| Condition | Mechanism | Classic Presentation | Key Lab |
|---|---|---|---|
| Factor V Leiden | Resistance to Protein C | DVT/PE, especially with OCP use | ↑PTT; doesn't correct with mixing study |
| Antiphospholipid Ab | Ab against phospholipid-binding proteins | Recurrent miscarriages + DVT/stroke | ↑PTT (paradox), positive lupus anticoagulant |
| Polycythemia Vera | JAK2 mutation → ↑RBC | Budd-Chiari, pruritus after hot shower | ↓EPO (negative feedback), ↑Hct |
| PNH | GPI anchor defect → complement lysis | Budd-Chiari, hemolytic anemia, dark morning urine | Flow cytometry (CD55/CD59 absent) |
| Protein C/S deficiency | ↓anticoagulant → ↑clotting | Warfarin-induced skin necrosis (C deficiency) | ↓Protein C or S levels |
Antiphospholipid Syndrome Paradox
PTT is elevated (antibodies interfere with in vitro test) but patient is THROMBOTIC, not bleeding. Never use PTT elevation alone to diagnose a bleeding disorder — always confirm with mixing study and clinical context.
RR 94EP454
MI Free Wall Rupture, Tamponade & Pericardial Emergencies
- Free wall rupture: precipitously low BP + EKG signal present but no pulse = PEA; blood fills pericardium → acute tamponade
- Beck's triad of tamponade: hypotension + muffled heart sounds + JVD (can't forget JVD — distension, not collapse)
- Echocardiography confirms diagnosis; emergency pericardiocentesis is the treatment
- Pulsus paradoxus >10 mmHg with inspiration = tamponade (or severe asthma/COPD)
Free Wall Rupture vs. Other MI Complications
- Free wall rupture: sudden hemodynamic collapse + PEA; no murmur (contrast with VSD/papillary rupture which both have murmurs)
- Blood fills pericardium → cardiac tamponade → Beck's triad
- Occurs day 3–7: macrophage-mediated digestion of myocardial tissue weakens the wall
- Treatment: emergency surgical repair; pericardiocentesis temporizing only
PEA after MI = Free Wall Rupture Until Proven Otherwise
PEA (electrical activity on monitor, no palpable pulse) in the setting of a recent MI is a free wall rupture with tamponade until proven otherwise. Bedside echo confirms. Do NOT just run ACLS — this needs the OR.
RR 132EP633
STEMI, Sarcoidosis Cardiac Involvement & VTE in Pregnancy/Cancer
- VTE in cancer/pregnancy/post-surgery/post-MI: hypercoagulable state from immobility + endothelial disruption + activated coagulation cascade
- Sarcoidosis cardiac involvement: young woman + non-caseating granulomas + cardiac symptoms → restrictive CM pattern, arrhythmias, AV block; treat with steroids
- Beta blockers first in STEMI: reduce myocardial oxygen demand; esmolol (IV, short-acting) useful for acute rate/BP control
Sarcoidosis — Cardiac Manifestations
- Non-caseating granulomas infiltrate myocardium → fibrosis → restrictive pattern
- Arrhythmias: heart block (especially complete AV block), VTach, VFib
- Vignette: young Black woman + bilateral hilar adenopathy + syncopal episode → cardiac sarcoidosis
- Diagnosis: cardiac MRI (late gadolinium enhancement), FDG-PET; biopsy usually not of heart
- Treatment: systemic steroids; implantable defibrillator if arrhythmia risk high
Pharmacology
Cardiovascular pharmacology lives or dies on receptor physiology. Alpha-1 gives you vasoconstriction and reflex bradycardia; alpha-2 gives you sympatholysis and clonidine's role in HTN + opioid withdrawal; beta-1 gives you heart rate, contractility, and renin. Understanding these receptors unlocks pressors, antiarrhythmics, and the entire cardiac drug armamentarium. Amiodarone is a special case — it does everything but carries thyroid and pulmonary toxicity that no one should miss.
EP333
The Clutch Pressor & Inotrope Podcast
- Septic shock pressor order: (1) norepinephrine first-line, (2) vasopressin second-line, (3) epinephrine third-line — memorize this sequence cold
- Digoxin mechanism: inhibits Na/K-ATPase → ↑intracellular Na → Na/Ca exchanger fails → ↑intracellular Ca → ↑inotropy; toxicity reversal = anti-dig Fab fragments
- Digoxin K⁺ paradox: digoxin causes hyperkalemia (blocks K⁺ entry into cells); but hypokalemia predisposes to toxicity (more binding sites for digoxin on Na/K-ATPase)
- Milrinone (PDE inhibitor): ↑cAMP in heart = ↑inotropy; ↑cAMP in vessels = vasodilation/↓afterload → widens pulse pressure; no mortality benefit long-term
- Phenylephrine/ephedrine: pure alpha-1 agonists → vasoconstriction → reflex bradycardia; used for anesthesia-induced hypotension
Inotropes vs. Vasopressors
| Drug | Class | Mechanism | Use Case | Pitfall |
|---|---|---|---|---|
| Digoxin | Inotrope | Na/K-ATPase inhibitor → ↑Ca | HFrEF, AFib rate control | Hypokalemia → toxicity; toxicity = yellow vision, hyperkalemia, arrhythmias |
| Dobutamine | Inotrope (β1 agonist) | ↑HR, ↑contractility | Cardiogenic shock, chemical stress test | ↑renin → ↑aldosterone → hypokalemia |
| Milrinone | PDE inhibitor (inotrope + vasodilator) | ↑cAMP → ↑inotropy + vasodilation | Acute HF (short-term) | Widens pulse pressure; no mortality benefit |
| Norepinephrine | Vasopressor (α1 + β1) | Primarily α1 vasoconstriction | Septic shock (first-line) | — |
| Vasopressin | Vasopressor (V1 receptor) | GQ → vasoconstriction | Septic shock (second-line); vWD (desmopressin form); nocturnal enuresis | — |
| Epinephrine | Vasopressor (α + β) | α1 + β1 + β2 | Anaphylaxis (β2), ACLS, septic shock (third-line) | Repeat dosing in anaphylaxis; don't stop at one dose |
| Phenylephrine | Vasopressor (pure α1) | Vasoconstriction only | Anesthesia-induced hypotension | Reflex bradycardia (baroreceptor response) |
Digoxin K⁺ Conundrum — Must Memorize Both Directions
- Digoxin → hyperkalemia: blocks Na/K-ATPase → K⁺ cannot enter cells → K⁺ stays in blood
- Hypokalemia → digoxin toxicity: low serum K⁺ → more unoccupied binding sites on Na/K-ATPase → digoxin binds more → toxicity at lower dose
- Clinical: patients on thiazide diuretics + digoxin → watch for hypokalemia → digoxin toxicity even at "therapeutic" levels
Vasopressin's Non-Shock Uses
Desmopressin = ADH analogue. Uses: (1) nocturnal enuresis in children >5 yo, (2) von Willebrand disease — releases vWF from Weibel-Palade bodies, (3) uremic bleeding in ESRD — improves platelet function, (4) central DI. On Step 2/3, vasopressin questions are often about these non-shock applications.
EP346
Cardiovascular Pharmacology Part 1 — Antiarrhythmics & Rate Control
- VTach (hemodynamically stable): wide complex regular tachyarrhythmia → amiodarone (first-line); if unstable → synchronized cardioversion; pulseless VTach → unsynchronized (defibrillation)
- Procainamide: Class IA antiarrhythmic; slow acetylators accumulate it → drug-induced lupus; give atropine for bradycardia from CCB overdose (blocks AV node slowing)
- Calcium channel blocker (dihydropyridine) peripheral edema: arteriolar dilation → ↑capillary hydrostatic pressure → edema; fix with ACE inhibitor/ARB (dilates postcapillary venules → lowers hydrostatic pressure)
- Reflex tachycardia: any vasodilator (dihydropyridine CCB, nitrates, hydralazine) → ↓SVR → ↓BP → baroreceptors → sympathetic discharge → ↑HR
Antiarrhythmic Classes — Quick Reference
| Class | Mechanism | Drugs | Use | Toxicity |
|---|---|---|---|---|
| IA | Na⁺ channel blocker (intermediate) | Quinidine, Procainamide, Disopyramide | AFib, VTach | Procainamide → drug-induced lupus (slow acetylators) |
| IB | Na⁺ channel blocker (fast off) | Lidocaine, Mexiletine | Acute VTach, post-MI arrhythmia | CNS toxicity (tinnitus, seizures) |
| IC | Na⁺ channel blocker (slow off) | Flecainide, Propafenone | Structurally normal heart AFib | Pro-arrhythmic; avoid post-MI |
| II | Beta blockers | Metoprolol, Esmolol, Propranolol | AFib rate control, SVT, post-MI | Bradycardia, bronchospasm |
| III | K⁺ channel blocker (↑refractory period) | Amiodarone, Sotalol, Dofetilide | VFib, VTach, AFib | Amiodarone: thyroid, pulmonary, liver, corneal deposits |
| IV | Non-DHP CCB | Verapamil, Diltiazem | AFib/flutter rate control, SVT | Bradycardia, constipation |
CCB-Induced Edema Fix
Dihydropyridine CCBs (amlodipine, nifedipine) → dilate arterioles → ↑capillary pressure → pedal edema. Fix: add ACE inhibitor or ARB. The venule dilation from ACE/ARB reduces capillary hydrostatic pressure. This is NOT heart failure — the mechanism is purely hemodynamic.
EP347
Cardiovascular Pharmacology Part 2 — Digoxin Deep Dive, Epinephrine & Magnesium
- Digoxin toxicity: yellow/green visual halos + GI symptoms + arrhythmias (PVCs, bradycardia, AV block); reverse with anti-dig Fab fragments
- Epinephrine in anaphylaxis: first-line; repeat if no response — never stop at one dose; β2 → bronchodilation, α1 → vasoconstriction to counteract distributive shock
- Magnesium in preeclampsia: give MgSO4 when SBP ≥160 to prevent eclampsia seizures; MgSO4 toxicity = loss of DTRs → respiratory arrest; antidote = calcium gluconate
- Atropine for CCB bradycardia: CCBs slow AV node conduction; atropine (muscarinic antagonist) blocks parasympathetic slowing → ↑conduction speed through AV node
- Epinephrine second-line for septic shock: after norepinephrine fails (not vasopressin — vasopressin is second, epinephrine is third)
Digoxin Toxicity
- Classic triad: yellow/green visual halos + GI (nausea, vomiting) + arrhythmias (PAT with block, bradycardia, PVCs)
- Predisposing: hypokalemia (most common — e.g., concurrent diuretics), hypomagnesemia, renal failure (↓clearance), hypothyroidism
- Treatment: hold dig, correct electrolytes; anti-dig Fab (Digibind) for severe cases
- Gynecomastia is a known side effect of digoxin
Magnesium Sulfate — Key Points
- Drug of choice for eclampsia / preeclampsia seizure prophylaxis when BP ≥160/110
- Also drug of choice for torsades de pointes (polymorphic VTach)
- Toxicity monitoring: DTRs first to go (loss of patellar reflex = early warning); respiratory arrest = lethal
- Antidote: calcium gluconate (NOT calcium chloride — too irritating peripherally)
Torsades Connection
Torsades de pointes = polymorphic VTach from prolonged QT. Causes: hypokalemia, hypomagnesemia, type IA/III antiarrhythmics, some antipsychotics, macrolides. Treatment = IV magnesium regardless of Mg level + remove offending drug.
EP471
Alpha-1 Receptors and The USMLEs
- Alpha-1 locations: blood vessels (vasoconstriction) + bladder neck (urinary retention) + pupils (mydriasis); activation raises BP; blockade lowers BP + opens bladder
- Alpha-1 blockers for BPH: tamsulosin, prazosin, doxazosin — open bladder neck; long-term BPH use 5-alpha-reductase inhibitors (finasteride) to shrink prostate
- First-line HTN drugs: thiazides, ACE inhibitors/ARBs, dihydropyridine CCBs — alpha-1 blockers are NOT first-line; exception = pheochromocytoma (alpha-block first, then beta-block)
- Cocaine intoxication: ↑catecholamine release → must alpha-block FIRST, then beta-block; giving beta blocker alone → unopposed alpha → severe hypertension/coronary spasm
- Pseudoephedrine / phenylephrine: alpha-1 agonists → vasoconstrict nasal vessels → ↓rhinorrhea; can also raise BP → avoid in uncontrolled hypertension
Alpha-1 Receptor Map
| Location | Activation Effect | Blockade Effect | Clinical Use |
|---|---|---|---|
| Blood vessels | Vasoconstriction ↑BP | Vasodilation ↓BP | Phenylephrine for anesthesia hypotension |
| Bladder neck | Urinary retention | ↑urine flow | Tamsulosin/prazosin for BPH |
| Pupil (dilator) | Mydriasis | Miosis | Horner's (α1 block): ptosis + miosis + anhidrosis |
| Nasal mucosa vessels | Vasoconstriction, ↓secretion | — | Pseudoephedrine for congestion |
Cocaine / Pheochromocytoma Rule: Alpha Block First
If catecholamines are in excess (cocaine, pheochromocytoma), ALWAYS alpha-block first. Giving a beta blocker first → removes β2 vasodilation while leaving α1 vasoconstriction unopposed → hypertensive crisis + coronary spasm. Phenoxybenzamine (irreversible α blocker) used pre-op in pheochromocytoma.
EP472
Alpha-2 Receptors and the USMLEs
- Alpha-2 = inhibitory Gi-coupled: presynaptic autoreceptor — activation → ↓NE release; net effect is sympatholysis → ↓BP (paradoxically via reducing NE production)
- Clonidine (α2 agonist): lowers BP by ↓NE release; treats opioid withdrawal (both mu and α2 are inhibitory Gi → same intracellular pathway → compensate for opioid withdrawal)
- α-methyldopa: false neurotransmitter that activates α2 → preferred antihypertensive in pregnancy (safe profile); causes Coombs-positive hemolytic anemia
- Clonidine withdrawal: abrupt discontinuation → rebound hypertensive crisis (same as beta-blocker withdrawal)
Alpha-2 Agonists — Clinical Applications
| Drug | Use | Mechanism | Key Toxicity |
|---|---|---|---|
| Clonidine | HTN, opioid withdrawal, ADHD | α2 agonist → ↓NE release → vasodilation | Rebound HTN if stopped abruptly; drowsiness |
| α-Methyldopa | Hypertension in pregnancy | False NT → activates α2 | Coombs+ hemolytic anemia, hepatotoxicity |
| Dexmedetomidine | ICU sedation | α2 agonist → ↓sympathetic tone | Bradycardia, hypotension |
Why Clonidine Works for Opioid Withdrawal
Opioids act on mu receptors (Gi-coupled). Withdrawal = rebound sympathetic surge (tachycardia, HTN, diaphoresis, piloerection). Alpha-2 receptors are also Gi-coupled → clonidine activates the same downstream pathway → suppresses sympathetic rebound. It does NOT treat the craving — only the autonomic symptoms.
EP474
Beta-1 Receptors and the USMLEs
- Beta-1 locations: heart (↑HR + ↑contractility) + JG cells (↑renin) + adipose (lipolysis); stimulation = sympathetic cardiac drive
- SVT management: (1) vagal maneuver first, (2) adenosine IV if vagal fails, (3) beta blocker or non-DHP CCB for recurrence prevention
- Thyroid storm: beta blocker FIRST (not antithyroid drug); esmolol (IV, short-acting β1 blocker) also inhibits peripheral T4→T3 conversion via 5'-deiodinase
- Aortic dissection: beta blocker FIRST for acute management (↓HR, ↓dP/dt); esmolol used; surgical repair for type A (ascending), medical management for type B (descending)
- AFib: beta blocker for rate control + anticoagulation; if valvular AFib (especially mitral stenosis) → warfarin only (not DOAC)
Beta-1 Receptor Clinical Integration
| Situation | Drug | Mechanism |
|---|---|---|
| Aortic dissection (acute) | IV esmolol (β1 blocker) | ↓HR + ↓dP/dt → reduces aortic shear stress |
| Thyroid storm | Propranolol or esmolol FIRST | β-block + ↓T4→T3 (5'-deiodinase inhibition) |
| SVT (refractory to vagal) | Adenosine (6 mg IV fast push) | ↑K⁺ conductance → hyperpolarizes AV node → breaks reentry |
| AFib rate control | Metoprolol or diltiazem | Slow AV nodal conduction |
| Chemical stress test | Dobutamine (β1 agonist) | Simulates exercise-induced ischemia |
| Beta blocker OD / CCB OD | Glucagon IV | Bypasses receptor → ↑cAMP directly |
Esmolol — The Acute Care Beta Blocker
Esmolol = IV, ultra-short-acting β1 selective blocker. Half-life ~9 minutes. Used when you need rapid, titratable beta blockade: aortic dissection, thyroid storm, SVT, perioperative HTN. Easy to titrate off if patient decompensates.
Beta Blockers in Specific Conditions
- Post-MI: reduce mortality (↓myocardial O2 demand, antiarrhythmic)
- HFrEF (chronic): metoprolol succinate, carvedilol, bisoprolol → improve survival (not in acute decompensation)
- Contraindications: decompensated HF, cocaine intoxication (unopposed α), reactive airway disease (β2 blockade → bronchospasm)
RR 91EP438
Amiodarone Toxicity & Thyroid-Cardiac Axis
- Amiodarone = Class III antiarrhythmic (K⁺ channel blocker); broad-spectrum — also has Class I, II, IV activity; used for VFib, VTach, AFib
- Amiodarone toxicity: pulmonary fibrosis, thyroid dysfunction (hypo or hyperthyroid — iodine-rich), corneal microdeposits (halos), hepatotoxicity, photosensitivity (blue-grey skin), peripheral neuropathy
- Thyroid and heart rate connection: thyroid hormone inserts β1 receptors on cardiac myocytes → hypothyroid = HR <60; hyperthyroid = tachycardia
- Synchronized vs. unsynchronized cardioversion: stable VTach → synchronized; pulseless VTach/VFib → defibrillation (unsynchronized)
Amiodarone Toxicity — All Organs
- Lungs: pulmonary fibrosis / interstitial pneumonitis (most dangerous); new dyspnea on amiodarone → CXR → CT chest → pulmonary consult
- Thyroid: iodine-rich → can cause both hypothyroidism (Wolff-Chaikoff) and hyperthyroidism (Jod-Basedow); check TFTs regularly
- Eyes: corneal microdeposits → halos around lights (almost universal); not a reason to stop
- Liver: transaminase elevation → hepatotoxicity with long-term use
- Skin: photosensitivity → blue-grey discoloration with sun exposure
- Nervous system: peripheral neuropathy, proximal myopathy
Amiodarone Monitoring Protocol
Every patient on amiodarone needs regular: TFTs (thyroid), LFTs (liver), CXR or CT (lungs), slit-lamp exam (eyes). On NBME: new dyspnea in a patient on amiodarone = pulmonary toxicity until proven otherwise. New visual halos = corneal deposits (benign, don't stop drug for this alone).
RR 90EP434
Digoxin Gynecomastia, Spironolactone in HFrEF & PNMT Enzyme
- Digoxin causes gynecomastia: structurally similar to estrogen; high-yield association for NBME questions about gynecomastia differentials
- Spironolactone in HFrEF: aldosterone antagonist → mortality benefit in HFrEF; side effect = gynecomastia (another NBME gynecomastia cause); also watch for hyperkalemia
- PNMT enzyme: converts NE → epinephrine; induced by cortisol (from adjacent adrenal cortex) — explains why adrenal medulla makes epinephrine only when cortisol is present
- NE → epinephrine conversion: requires PNMT; Gi-coupled (alpha-2) receptor on presynaptic terminal inhibits further NE release (autoreceptor feedback)
HFrEF — Drugs That Improve Mortality
- ACE inhibitor / ARB: reduce afterload + prevent cardiac remodeling
- Beta blocker (metoprolol succinate, carvedilol, bisoprolol): reduce sympathetic overdrive; start only in STABLE patients
- Spironolactone/eplerenone: aldosterone antagonist; reduces fibrosis + prevents hypokalemia from loop diuretics; mortality benefit proven
- ARNI (sacubitril/valsartan): newer; ↑natriuretic peptides + ARB effect; superior to ACE inhibitor for mortality
- Digoxin: reduces hospitalizations but NO mortality benefit; still used for symptom control in HFrEF + AFib
Gynecomastia Drug List — NBME Loves This
Drugs causing gynecomastia: Spironolactone, Digoxin, Cimetidine, Ketoconazole, estrogens, finasteride, anabolic steroids, marijuana, antipsychotics. When NBME asks "which drug is causing this man's breast enlargement?" — check for spironolactone and digoxin first in cardiology contexts.
Valvular & Structural
Valvular disease is tested through three lenses: hemodynamic consequences (widened pulse pressure in AR), physical exam integration (TEE indications), and management decisions (when to anticoagulate, when to cardiovert, when to operate). Aortic regurgitation is the archetype for teaching compensatory mechanisms; TEE indications are a simple memory list once you know that the esophagus lies posterior to the left atrium.
EP490
The Clutch TEE Podcast
- TEE vs. TTE principle: TEE has superior sensitivity/specificity because esophagus is posterior to the left atrium — gives superb views of structures TTE misses
- TEE Indication 1 — Cryptogenic stroke / PFO: young patient + stroke without classic risk factors + cardiac shunt suspected → TEE with bubble study to visualize PFO/ASD
- TEE Indication 2 — Pre-cardioversion for AFib: must rule out left atrial appendage thrombus before cardioversion; TEE is the modality of choice for LAA visualization
- TEE Indication 3 — Mechanical valve dysfunction: new dyspnea + elevated bilirubin (hemolysis from mechanical valve turbulence) → TEE to assess valve function
- TEE complication: esophageal rupture (rare but lethal); presents with mediastinal air + subcutaneous emphysema + fever post-procedure → confirm with gastrografin (water-soluble contrast); never barium if esophageal rupture suspected
TEE Indications — All High-Yield
| Indication | Why TEE (not TTE) | What You're Looking For |
|---|---|---|
| Cryptogenic stroke (embolic) | LAA and PFO poorly seen on TTE | PFO, ASD, VSD; bubble study shows R→L shunt |
| Pre-cardioversion in AFib | Only modality that clearly sees LAA | Thrombus in LAA (could embolize with cardioversion) |
| Infective endocarditis | Higher sensitivity for vegetations | Vegetations, abscesses, perivalvular extension |
| Aortic dissection (unstable) | Portable, fast, no contrast needed | Intimal flap, dissection extent, pericardial effusion |
| Mechanical valve dysfunction | Better resolution near LA | Thrombus, regurgitation, valve dehiscence |
| Hemodynamically unstable, TTE non-diagnostic | Better views when TTE fails | Assess LV/RV function, pericardial effusion |
Esophageal Rupture After TEE
Fever + subcutaneous emphysema + chest pain after TEE = esophageal perforation. Confirm with GASTROGRAFIN (water-soluble contrast). Never barium — barium in the mediastinum causes severe mediastinitis. Emergency surgical repair required.
LAA Thrombus and AFib — The Logic
- AFib → blood stasis in left atrial appendage (low-flow appendage) → thrombus forms
- Cardioversion → mechanical contraction returns → thrombus can embolize → stroke
- If AFib <48 hours duration → can cardiovert without TEE (thrombus unlikely to have formed)
- If AFib >48 hours OR unknown duration → TEE to exclude LAA thrombus, OR anticoagulate 3 weeks before cardioversion
EP496
Aortic Regurgitation — Demystified
- Widened pulse pressure: SBP high (↑SV from regurgitant + forward flow) + DBP low (blood leaks back into LV during diastole → aortic pressure can't be maintained) → e.g., 140/40
- Frank-Starling in AR: LV receives blood from both LA and aorta (two sources of preload) → ↑EDV → ↑SV → ↑CO; compensatory but eventually fails (eccentric hypertrophy)
- Chronic AR murmur: early diastolic decrescendo murmur, best heard at left 3rd ICS with patient leaning forward; radiates to left lower sternal border
- Austin Flint murmur: mid-diastolic rumble at apex in severe AR — regurgitant jet from aorta hits anterior mitral leaflet → functional mitral stenosis sound; no actual stenosis
- Eponymous signs in AR: Corrigan's pulse (water-hammer), de Musset's sign (head bobbing), Quincke's sign (nailbed pulsation), Duroziez's sign (femoral bruit)
Aortic Regurgitation — Hemodynamic Cascade
- Aortic valve incompetent → blood regurgitates from aorta back into LV during diastole
- Aortic diastolic pressure cannot be maintained → ↓DBP
- LV receives extra preload (from LA + from aorta) → LV volume overload → ↑EDV
- ↑EDV → Frank-Starling → ↑SV → ↑SBP
- Net: high SBP + very low DBP = widened pulse pressure
Aortic Regurgitation — Physical Exam Signs
| Sign | Finding | Mechanism |
|---|---|---|
| Corrigan's pulse (water-hammer) | Bounding, forceful, then rapidly collapsing pulse | High SV ejection + low diastolic runoff |
| de Musset's sign | Head bobbing with each heartbeat | High pulse pressure transmitted to head |
| Quincke's sign | Visible nailbed pulsation | Widened pulse pressure reaching peripheral capillaries |
| Duroziez's sign | Systolic and diastolic bruit over femoral artery | High-pressure forward + backward flow |
| Austin Flint murmur | Mid-diastolic rumble at apex | Regurgitant jet hits anterior mitral leaflet → mimics mitral stenosis |
Austin Flint vs. Mitral Stenosis
Both produce mid-diastolic rumbles at the apex. Austin Flint (in severe AR): no opening snap, no loud S1. Mitral stenosis: opening snap present, loud S1, history of rheumatic fever. The regurgitant jet in AR physically displaces the anterior mitral leaflet — no structural stenosis.
RR 104EP487
Aortic Dissection — Diagnosis & Management
- Classic presentation: tearing/ripping chest pain radiating to the back + unequal blood pressures in arms + wide mediastinum on CXR; Marfan syndrome is a major risk factor (cystic medial necrosis)
- Stable patient: CT angiography of chest with contrast (gold standard)
- Unstable patient: bedside TEE (fast, no contrast, can be done at bedside); do NOT delay for CT
- Type A (ascending aorta): surgical emergency; Type B (descending only) → medical management with IV beta blocker first (↓dP/dt)
- First pharmacotherapy: IV beta blocker (esmolol) to lower heart rate and reduce aortic wall stress before adding vasodilators
Aortic Dissection — Stanford Classification
| Type | Involves | Treatment | Urgency |
|---|---|---|---|
| Type A | Ascending aorta (± descending) | Emergency surgical repair | Surgical emergency |
| Type B | Descending aorta only (distal to L subclavian) | Medical: β-blocker + vasodilator; surgery if complicated | Urgent medical |
Marfan Syndrome — Aortic Risk
- FBN1 gene mutation → defective fibrillin-1 → cystic medial necrosis of aortic media → aorta cannot withstand pressure → dissection/aneurysm
- Prophylactic β-blockers (atenolol) or ARBs (losartan) to slow aortic root dilation
- Annual echocardiography to monitor aortic root diameter
Heart Failure & Hypertension
Secondary hypertension is the high-yield subset: each cause (renal artery stenosis, primary hyperaldosteronism, pheochromocytoma, Cushing's) has a signature lab pattern. Heart failure management rewards knowing which drugs improve mortality (ACE/ARB, beta blockers, spironolactone, ARNI) vs. which only improve symptoms (digoxin, diuretics). OSA-induced hypertension via ANP suppression adds a physiology layer that connects pulmonary and cardiovascular pathways.
EP360
The Clutch Secondary Hypertension Podcast
- Conn's syndrome (primary hyperaldosteronism): HTN + hypokalemia + metabolic alkalosis; low renin (negative feedback); plasma aldosterone:renin ratio >30; treat with spironolactone (bilateral hyperplasia) or adrenalectomy (adenoma)
- Renovascular HTN (renal artery stenosis): young woman with HTN → fibromuscular dysplasia (most common in women <50); abdominal bruit; high renin; diagnose with duplex ultrasound or CTA; treat with angioplasty
- Pheochromocytoma: paroxysmal HTN + diaphoresis + headache + palpitations; diagnose with 24h urine catecholamines/metanephrines; alpha-block first, then beta-block, then surgery
- Cushing's syndrome: cortisol excess → mineralocorticoid receptor activity → HTN + hypokalemia + metabolic alkalosis + buffalo hump + moon facies; screen with 24h urine cortisol or overnight 1 mg dexamethasone suppression test
- Coarctation of the aorta: HTN in upper extremities + low BP in lower extremities; rib notching on CXR; associated with bicuspid aortic valve; repair surgically
Secondary HTN — Lab Patterns
| Cause | Renin | Aldosterone | K⁺ | Other |
|---|---|---|---|---|
| Primary hyperaldosteronism (Conn's) | ↓ | ↑↑ | ↓ | Metabolic alkalosis; aldosterone:renin >30 |
| Renovascular HTN (RAS) | ↑↑ | ↑ | ↓ | Abdominal bruit; unilateral kidney atrophy |
| Pheochromocytoma | ↑ | ↑ | Normal | ↑urine metanephrines; paroxysmal symptoms |
| Cushing's syndrome | Normal/↓ | Normal | ↓ | ↑cortisol; buffalo hump; metabolic alkalosis |
| Coarctation of aorta | ↑ | ↑ | ↓ | Upper > lower extremity BP; rib notching |
Conn's Syndrome Workup Sequence
(1) Resistant HTN + hypokalemia + metabolic alkalosis → suspect Conn's. (2) Check plasma aldosterone:renin ratio (PAC:PRA) → if >30, diagnostic. (3) CT adrenals to look for adenoma. (4) If CT inconclusive → adrenal vein sampling (bilateral catheterization). (5) Unilateral adenoma → adrenalectomy; bilateral hyperplasia → spironolactone or eplerenone.
RR 87EP426
Hypertensive Urgency/Emergency, IIH & Arteriovenous Nicking
- Hypertensive emergency: severely elevated BP + end-organ damage (papilledema, encephalopathy, AKI, MI) → lower BP immediately with IV agents (nicardipine, labetalol, sodium nitroprusside)
- Hypertensive urgency: severely elevated BP + NO end-organ damage → lower gradually over 24–48h with oral agents
- AV nicking on fundoscopy: chronic hypertension → thickened arteriolar walls compress underlying venules at crossing points; associated with chronic poorly controlled HTN
- IIH (pseudotumor cerebri): obese young woman + headache + papilledema + elevated opening pressure + normal MRI; treat with acetazolamide ± weight loss; LP is both diagnostic and therapeutic
Hypertensive Emergency — IV Drug Options
- Nicardipine: DHP CCB, titratable IV infusion; safe in most scenarios
- Labetalol: combined α1 + β blocker; preferred in pregnancy (eclampsia)
- Sodium nitroprusside: powerful venous + arterial dilator; cyanide toxicity with prolonged use or renal failure
- Hydralazine: used in pregnancy; pure arterial vasodilator
- Phentolamine: pure α blocker; preferred for pheochromocytoma crisis
RR 83EP413
OSA, OHS, ANP & Blood Pressure Regulation
- OSA/OHS → HTN pathway: hypoxemia → chronic sympathetic activation + ↑ADH → volume retention → HTN; also ↑ANP released (trying to counteract volume overload) → natriuresis attempts
- ANP (atrial natriuretic peptide): released from atria when volume-overloaded; causes natriuresis + vasodilation + ↓aldosterone; body's natural attempt to lower BP
- When hypertensive, body wants: natriuresis (excrete Na), ↓ADH (avoid water retention), ↑ANP — all logical responses to high-pressure state
- Pregnancy and BP: normal pregnancy → ↓SVR (progesterone) → ↓BP; BP should be lower in normal pregnancy; rising BP = pathological (pre-eclampsia)
ANP vs. BNP
| Peptide | Source | Trigger | Clinical Use |
|---|---|---|---|
| ANP | Atrial cardiomyocytes | Atrial stretch (↑volume) | Natriuresis, vasodilation; not typically measured clinically |
| BNP | Ventricular cardiomyocytes | Ventricular wall stress (↑pressure or volume) | Diagnosed HF; >100 pg/mL suggests HF; used to guide diuresis |
| NT-proBNP | Cleaved from proBNP | Same as BNP | Longer half-life; better for monitoring chronic HF |
RR 111EP509
Adrenergic Receptors in Heart Failure & Step 2 Basic Sciences
- Step 2/3 basic science trend: NBME increasingly testing Step 1 concepts on Step 2/3; receptor physiology, basic pharmacology, and pathophysiology are all fair game
- Alpha-1 integration: BPH (tamsulosin blocks α1 at bladder neck), anesthesia-induced hypotension (phenylephrine restores), nasal congestion (pseudoephedrine agonizes α1 in nasal vessels)
- 5-alpha reductase inhibitors: finasteride, dutasteride → ↓DHT → prostate shrinks → long-term BPH treatment; 6–12 months for effect
- First-line HTN summary: thiazide diuretics, ACE inhibitors/ARBs, DHP CCBs — do not use alpha-1 blockers as first-line unless specific indication (pheochromocytoma)
First-Line Hypertension Drugs — Know the Exceptions
- Default first-line: thiazide, ACE/ARB, or DHP CCB (all acceptable)
- African Americans: avoid ACE/ARB as first-line unless comorbidity present (DM, HF)
- Diabetes + HTN: ACE inhibitor or ARB preferred (renoprotective)
- HFrEF + HTN: ACE/ARB + beta blocker (both treat HTN and improve HF mortality)
- Conn's syndrome: spironolactone is ideal (treats both HTN and the underlying aldosterone excess)
- Pheochromocytoma: alpha blocker (phenoxybenzamine) first, then beta blocker preoperatively
- Pregnancy: methyldopa, labetalol, nifedipine — never ACE/ARB (teratogenic)
HY Clinical Signs & Integration
Clinical cardiology at the USMLE level is about connecting exam findings to pathophysiology — not memorizing lists. Kussmaul's sign, pulsus paradoxus, and the preload-murmur relationships all derive from the same venous return mechanics. SVT management, anion gap equations, and the osmolal gap are mathematical integrations that reward understanding the formulas rather than memorizing normal ranges. These episodes tie all the cardiology content into testable clinical scenarios.
EP540
Floridly HY Cardiac Signs, Part 1
- Kussmaul's sign: JVD that worsens (doesn't collapse) with inspiration → constrictive pericarditis; heart encased in calcium cannot expand with ↓intrathoracic pressure → JVs distend instead of emptying
- Pulsus paradoxus (>10 mmHg drop in SBP with inspiration): cardiac tamponade — pericardium full of fluid → RV cannot expand into pericardium → all RV expansion goes through IVS into LV → LV preload crashes
- Coronary steal principle: dipyridamole/adenosine dilate normal coronary arteries; diseased segments are already maximally dilated → blood steals away from ischemic territory → used in chemical stress testing for patients who cannot exercise
- Murmur rules summary: most murmurs ↑ with ↑preload (supine, squatting); MVP and HOCM ↑ with ↓preload (standing, Valsalva) — exceptions because ↑preload transiently corrects the structural abnormality
Constrictive Pericarditis vs. Cardiac Tamponade
| Feature | Constrictive Pericarditis | Cardiac Tamponade |
|---|---|---|
| JVP with inspiration | ↑ (Kussmaul's sign) | Normal or ↑ (no Kussmaul's) |
| Pulsus paradoxus | Absent or mild | Present (>10 mmHg) |
| Pericardium | Fibrotic/calcified (rigid) | Fluid-filled (compressive) |
| Heart sounds | Pericardial knock (early S3-like) | Muffled |
| CXR | Calcification on lateral view | Enlarged cardiac silhouette ("water bottle") |
| Treatment | Pericardiectomy | Pericardiocentesis |
Coronary Steal — Chemical Stress Test Agents
- Dipyridamole / adenosine: inhibit adenosine breakdown → ↑adenosine → vasodilates normal coronaries → blood steals from diseased territory
- Dobutamine: β1 agonist → ↑HR + ↑contractility → increases myocardial O2 demand → unmasks ischemia in supply-limited territories
- Both used when patient cannot exercise on treadmill
- Contraindication for dipyridamole/adenosine: severe bronchospasm (theophylline is the antidote)
EP542
Floridly HY Cardiac Signs, Part 2
- RV afterload: pulmonary HTN (from left HF or BMPR2 mutation), PE (acute obstruction), Eisenmenger's (L→R shunt reversal) — all increase RV wall stress
- Eisenmenger's physiology: uncorrected L→R shunt (VSD, ASD) → chronic ↑pulmonary flow → pulmonary HTN → RV pressure exceeds LV pressure → shunt reverses R→L → cyanosis
- LV afterload: aortic stenosis is the primary culprit (outflow obstruction); also systemic HTN (↑SVR)
- Aortic stenosis severity: AS murmur intensity DECREASES in HF (less flow across the valve despite same obstruction); paradoxical finding — severe AS can be quiet on exam
Eisenmenger's Syndrome
- Original defect: L→R shunt (VSD most common, also ASD, PDA)
- ↑pulmonary blood flow → pulmonary vascular remodeling → pulmonary HTN → RV hypertrophy
- When pulmonary pressure exceeds systemic → shunt reverses R→L → deoxygenated blood enters systemic circulation → cyanosis
- Finger clubbing + polycythemia (compensatory) + paradoxical emboli
- Repair of the defect is now CONTRAINDICATED (fixing the hole without addressing pulmonary HTN can be fatal)
Pulmonary Arterial Hypertension (PAH) — Key Points
- BMPR2 mutation → idiopathic PAH (young women predominantly)
- Mechanism: loss of BMPR2 → uncontrolled smooth muscle proliferation in pulmonary arteries → progressive obliteration
- Treatments: PDE5 inhibitors (sildenafil), endothelin receptor antagonists (bosentan), prostacyclin analogues (epoprostenol)
- Most common cause of PAH: left heart disease (mitral stenosis, HFpEF) → post-capillary pulmonary HTN
Aortic Stenosis Pitfall
Severe AS can be silent. When the LV is failing (low EF, low CO), there's not enough flow to generate the loud murmur. Don't reassure yourself with a quiet chest exam — check echo. Paradoxically, mild AS (good flow) sounds louder than severe AS with HF.
EP600
Intuition & Integrations With Select Equations
- Fick's Law of diffusion: diffusion ∝ (surface area × pressure gradient × solubility) / (distance × molecular weight); fibrotic lung disease thickens the membrane → ↓diffusion → hypoxemia
- ARDS mechanism via Fick: inflammatory mediators → ↑pulmonary vascular permeability → fluid coats alveolar walls → ↑membrane thickness → ↓diffusion efficiency → profound hypoxemia
- Mechanical ventilation in ARDS: ↑pressure gradient (PEEP) → overcomes diffusion barrier; the equation justifies why PPV helps
- Diffusion vs. perfusion-limited gas exchange: O2 is normally perfusion-limited (healthy); becomes diffusion-limited in fibrosis/ARDS; CO is always diffusion-limited (used in DLCO testing)
Diffusion Capacity (DLCO) — Clinical Interpretation
| Condition | DLCO | Mechanism |
|---|---|---|
| Pulmonary fibrosis | ↓↓ | Thickened alveolar membrane |
| ARDS | ↓↓ | Diffuse alveolar flooding |
| Emphysema | ↓ | Loss of alveolar surface area |
| Polycythemia / pulmonary hemorrhage | ↑ | More Hb available to bind CO |
| Asthma (mild) | Normal | Airway disease, not alveolar |
EP625
The 5 USMLE "Gaps"
- Serum anion gap = Na − (Cl + HCO3); normal 8–12; elevated = unmeasured anions (MUDPILES: methanol, uremia, DKA, propylene glycol, isoniazid, lactic acidosis, ethylene glycol, salicylates)
- Urine anion gap = urinary (Na + K − Cl); negative = diarrhea (↑NH4Cl excretion); positive = RTA type 1 or 4 (↓ammonium excretion)
- Osmolal gap = measured osmolality − calculated osmolality (>10 = osmolal gap); elevated = toxic alcohol present (methanol, ethylene glycol, isopropanol)
- A-a gradient: normal <10; elevated = V/Q mismatch, diffusion impairment, R→L shunt; normal gradient with hypoxemia = hypoventilation (high PCO2)
- Delta-delta ratio: (measured AG − 12) / (24 − measured HCO3); <1 = concurrent NAGMA; >2 = concurrent metabolic alkalosis
The 5 Gaps — Quick Reference
| Gap | Formula | Normal | Elevated Means |
|---|---|---|---|
| Serum AG | Na − (Cl + HCO3) | 8–12 | Unmeasured anions (MUDPILES) |
| Urine AG | Na + K − Cl (urine) | Negative | Positive = RTA; Negative = GI HCO3 loss |
| Osmolal gap | Measured − Calculated Osm | <10 | Toxic alcohol present |
| A-a gradient | PAO2 − PaO2 | <10 | V/Q mismatch, shunt, diffusion issue |
| Delta-delta | (AG−12)/(24−HCO3) | 1–2 | <1 = NAGMA; >2 = metabolic alkalosis mixed |
RR 93EP449
SVT, Narrow vs. Wide Complex Arrhythmias & QRS Interpretation
- Narrow QRS + regular + fast HR = SVT (supraventricular tachycardia); conduction through ventricles is normal (His-Purkinje), so QRS is narrow
- SVT management: vagal maneuver first → adenosine 6 mg IV fast push → if recurrent: beta blocker or non-DHP CCB (verapamil/diltiazem)
- AFib vs. AFl vs. SVT: irregular + narrow = AFib; regular + narrow + "sawtooth" = AFL; regular + narrow + P-wave before each QRS = sinus tach; irregular spaces = AFib
- Wide QRS + regular + fast = VTach until proven otherwise; treat with amiodarone if stable, defibrillate if unstable/pulseless
Arrhythmia Quick Identification
| QRS Width | Regularity | Dx | Immediate Treatment |
|---|---|---|---|
| Narrow | Regular, very fast (>150) | SVT | Vagal maneuver → adenosine |
| Narrow | Irregularly irregular | AFib | Rate control (metoprolol); anticoagulate |
| Narrow | Regular, sawtooth P waves | Atrial flutter | Rate control; cardioversion |
| Wide | Regular, monomorphic | VTach | Stable: amiodarone; Unstable: sync cardioversion; Pulseless: defibrillate |
| Wide | Irregular, polymorphic | Torsades de pointes | IV magnesium; remove cause |
| Any | No pulse | VFib or pulseless VTach | Defibrillate immediately |
Special & Cross-System
This cluster captures cardiology at its intersections — COVID-19's prothrombotic and myocarditic complications, pediatric shunt physiology, amyloid's restrictive cardiomyopathy pattern, hemoglobin's A1c limitations in hemolytic states, and the EM procedural scenarios that touch cardiac anatomy. The RR 121 congenital heart segment is especially valuable: cyanotic vs. acyanotic defects with their genetic associations are a guaranteed NBME target.
EP300
COVID-19: Cardiovascular Complications
- SARS-CoV-2 binds ACE2 receptors on cardiac myocytes → direct cytopathic effect + immune-mediated myocarditis → dilated CM pattern
- COVID coagulopathy: endothelial injury + cytokine storm → hypercoagulable state → DVT, PE, stroke even in young patients; prophylactic anticoagulation is standard for hospitalized COVID patients
- Type 2 MI in COVID: demand ischemia from hypoxemia + tachycardia + fever → troponin elevation without coronary plaque rupture
- Troponin elevation in COVID: poor prognostic marker; elevated D-dimer = risk factor for VTE; ACE inhibitors/ARBs are NOT contraindicated despite ACE2 receptor binding
- Post-COVID myocarditis: post-acute COVID inflammatory cardiomyopathy; treat same as viral myocarditis (standard HF therapy)
COVID Cardiac Complications
- Myocarditis: ACE2-mediated myocardial infection + immune inflammation → dilated CM on echo (↓EF, enlarged LV)
- Arrhythmias: AFib, VTach from myocardial inflammation
- Type 2 MI: supply-demand mismatch; no plaque rupture; troponin elevated; treat underlying cause (O2, rate control), not PCI
- Pericarditis: post-COVID or acute; treat with aspirin + colchicine (same as any viral pericarditis)
ACE2 Receptor Paradox
SARS-CoV-2 enters cells via ACE2. Some early concern that ACE inhibitors/ARBs might upregulate ACE2 and worsen infection. Evidence shows NO increased risk — ACE inhibitors and ARBs should NOT be stopped in COVID patients who are on them for cardiac/renal indications.
EP326
Pediatric Cardiology & Hemodynamic Changes
- Transposition of great vessels: aorta arises from RV, pulmonary artery from LV → parallel circulations → incompatible with life unless shunt present (PDA, ASD, VSD); keep PDA open with PGE1; fix with balloon atrial septostomy then arterial switch
- Tetralogy of Fallot: (1) VSD, (2) overriding aorta, (3) RV hypertrophy, (4) pulmonic stenosis; most common cyanotic CHD; tet spells treated with knee-chest position + O2 + morphine + propranolol; boot-shaped heart on CXR
- PDA: prostaglandin keeps it open (used in cyanotic CHDs that need shunting); indomethacin (COX inhibitor) closes it in premature neonates; surgical ligation if fails
- VSD vs. ASD: both L→R shunts; VSD = holosystolic murmur at LLSB; ASD = fixed split S2 + systolic ejection murmur; both can → Eisenmenger's if uncorrected
Cyanotic vs. Acyanotic CHDs
| Defect | Type | Cyanotic? | Key Feature | Genetic/Association |
|---|---|---|---|---|
| VSD | L→R shunt | No (initially) | LLSB holosystolic murmur | Most common CHD overall |
| ASD | L→R shunt | No (initially) | Fixed split S2 | Down syndrome (endocardial cushion) |
| PDA | L→R shunt | No (initially) | Continuous "machinery" murmur | Prematurity, congenital rubella |
| Tetralogy of Fallot | R→L shunt | Yes | Boot-shaped heart; tet spells | 22q11 (DiGeorge) |
| Transposition (TGA) | Parallel circulations | Yes (at birth) | No mixing → incompatible with life | Maternal diabetes |
| Truncus arteriosus | R→L | Yes | Single great vessel from both ventricles | 22q11 deletion |
| TAPVR | R→L | Yes | All pulmonary veins drain into RA | — |
Tet Spell Management
Hypercyanotic spell in Tetralogy: child squats (↑SVR → forces more blood through pulmonary stenosis). In hospital: knee-chest position + 100% O2 + morphine (↓tachycardia, ↓hyperpnea) + propranolol (↓RV outflow tract spasm) + IV phenylephrine (↑SVR). Do NOT give digoxin or diuretics (worsens preload reduction).
EP367
The Clutch Amyloidosis Podcast
- Cardiac amyloidosis (AL type): most common cause of death in amyloidosis; restrictive cardiomyopathy pattern — stiff ventricles, diastolic dysfunction, preserved EF
- Echo pattern: "sparkling" or "granular" myocardial texture on echo + concentric LV thickening + normal or small LV cavity; echo findings out of proportion to ECG voltage (low voltage on ECG)
- Discordance sign: thick heart on echo + LOW voltage on ECG = amyloid (or other infiltrative CMs); normal hearts show high voltage with thickness
- Systemic amyloidosis associations: multiple myeloma (AL), chronic inflammation — RA, IBD (AA), hereditary (TTR mutations — African Americans, Val122Ile), aging (wild-type TTR)
Amyloidosis Types — Cardiac Focus
| Type | Protein | Associated With | Key Feature |
|---|---|---|---|
| AL amyloid | Immunoglobulin light chains | Multiple myeloma, MGUS | Most common type; most lethal cardiac involvement |
| AA amyloid | Serum amyloid A | Chronic inflammation (RA, IBD, osteomyelitis) | Renal involvement predominant; cardiac less common |
| TTR amyloid (hereditary) | Transthyretin (mutant) | Val122Ile mutation (African Americans) | Cardiac + peripheral neuropathy |
| TTR amyloid (senile/wild-type) | Transthyretin (normal) | Aging (>70, predominantly male) | Restrictive CM + carpal tunnel syndrome |
Low Voltage ECG + Thick Heart = Amyloid
Any patient with thick ventricular walls on echo (or MRI) but paradoxically LOW voltage on ECG → think amyloid or other infiltrative disease (sarcoidosis, hemochromatosis). The amyloid protein does not conduct electricity well despite adding mass. This discordance is pathognomonic.
EP409
The Clutch Hemoglobin Podcast
- HbA1c ≥6.5% = diabetes; but unreliable in chronic hemolysis (RBCs don't live long enough to glycate) → falsely LOW HbA1c → low sensitivity for DM in hemolytic anemia
- Oxygen-hemoglobin dissociation curve: right shift (↑2,3-BPG, ↑CO2, ↑H⁺, ↑temp) = ↓O2 affinity → ↑O2 delivery; left shift (fetal Hb, ↓2,3-BPG, CO, MetHb) = ↑O2 affinity → ↓delivery
- Lead poisoning: inhibits ALA dehydratase + ferrochelatase → heme synthesis disrupted → microcytic anemia + peripheral neuropathy (wrist drop/foot drop) + lead lines in bone on X-ray
- HbC: target cells on smear; mild hemolytic anemia; HbSC disease = milder sickle cell variant but higher thrombotic risk (especially retinal artery occlusion, splenic sequestration)
Oxygen-Hemoglobin Dissociation Curve Shifts
| Direction | Causes | Effect | Example |
|---|---|---|---|
| Right shift (↓affinity) | ↑2,3-BPG, ↑CO2, ↑H⁺, ↑Temp | ↑O2 unloading in tissues | Exercise, high altitude acclimatization |
| Left shift (↑affinity) | Fetal Hb, CO, MetHb, ↓2,3-BPG, ↓Temp | ↓O2 unloading; Hb holds O2 | CO poisoning (normal PaO2, low SaO2) |
CO Poisoning — The Pulse Ox Trap
CO binds Hb with 240× higher affinity than O2 → left-shifts curve → Hb won't release O2 to tissues → tissue hypoxia. BUT: pulse oximetry reads COHb as OxyHb → falsely normal SpO2. Patient appears well-oxygenated while cells are dying. Diagnosis: co-oximetry blood gas (measures COHb directly). Treatment: 100% O2 (competes with CO).
EP578
Quick & Dirty Emergency Medicine, Part 4
- Mediastinal air on CXR after thoracic trauma / TEE: esophageal injury → confirm with gastrografin; mediastinal air + subcutaneous emphysema = esophageal perforation
- Congenital diaphragmatic hernia: abdominal organs herniate into chest → compress developing lungs → pulmonary hypoplasia (not Potter sequence which is oligohydramnios)
- Pulmonary hypoplasia etiologies: Potter sequence (oligohydramnios), CDH, space-occupying lesions; lungs require fluid-filled expansion for proper alveolar development
- Penetrating chest trauma: mediastinal air → esophageal perforation → gastrografin study (NOT barium) for confirmation; hemothorax → chest tube; tension pneumothorax → needle decompression immediately
EM — Thoracic Emergencies
- Esophageal rupture (Boerhaave's): forceful vomiting + sudden chest pain + subcutaneous emphysema; CXR shows mediastinal air and left pleural effusion; confirm with gastrografin; emergency surgical repair
- Tension pneumothorax: tracheal deviation AWAY from affected side + absent breath sounds + hypotension; needle decompression at 2nd ICS MCL IMMEDIATELY — no time for CXR
- Cardiac tamponade (trauma): Beck's triad + hypotension; pericardiocentesis or pericardial window; FAST exam (bedside echo) is key in trauma bay
RR 121EP595
Congenital Heart Defects & Genetic Associations
- Ebstein's anomaly: downward displacement of tricuspid valve → "atrializarion" of RV → associated with lithium use in pregnancy; associated with ASD/PFO
- Down syndrome (trisomy 21): endocardial cushion defect (AV canal defect = ASD + VSD + abnormal AV valves)
- DiGeorge (22q11): truncus arteriosus + Tetralogy of Fallot; thymus aplasia + hypocalcemia (no parathyroids) + CHD
- Cyanotic CHDs → polycythemia: chronic hypoxemia → ↑EPO production → ↑RBC mass; polycythemia from cyanotic CHD has secondary (appropriate) ↑EPO
- Turner syndrome (45,X): coarctation of aorta + bicuspid aortic valve; most common CHD association
Genetic Syndromes & Cardiac Associations
| Syndrome | Genetics | Cardiac Defect | Other Key Features |
|---|---|---|---|
| Down syndrome | Trisomy 21 | Endocardial cushion defect (AV canal) | Epicanthal folds, single palmar crease, duodenal atresia |
| DiGeorge | 22q11 deletion | Truncus arteriosus, Tetralogy of Fallot | Thymus aplasia → T-cell deficiency; hypocalcemia |
| Turner | 45,X | Coarctation of aorta, bicuspid AV | Short stature, webbed neck, primary amenorrhea |
| Marfan | FBN1 | Aortic root dilation → dissection; MVP | Tall, arachnodactyly, lens dislocation (upward) |
| Williams | 7q11 deletion (elastin) | Supravalvular aortic stenosis | Elfin facies, hypercalcemia, "cocktail party" personality |
| Noonan | PTPN11 | Pulmonic stenosis, HCM | Phenotypically like Turner but normal karyotype; normal fertility |
| Ebstein's | Lithium exposure in utero | Tricuspid valve displacement + ASD/PFO | Cyanosis, tricuspid regurgitation |
RR 71EP370
Biostatistics Integrated with Cardiac Diagnosis Criteria
- Raising diagnostic threshold (e.g., DM from FBG ≥126 to ≥200): ↓sensitivity (more false negatives), ↑specificity (fewer false positives), ↓NPV, ↑PPV — the classic trade-off
- Sensitivity and NPV move together; Specificity and PPV move together — this relationship holds for any threshold change
- Application to troponin: very sensitive assay (high-sensitivity troponin) → excellent NPV → a negative result rules out MI; but ↑false positives (specificity drops)
- Fasting glucose ≥126 mg/dL: current DM threshold; A1c ≥6.5%; random glucose ≥200 + symptoms — any ONE confirms DM
Sensitivity/Specificity Trade-Off
| Change | Sensitivity | Specificity | NPV | PPV |
|---|---|---|---|---|
| ↑Threshold (stricter) | ↓ | ↑ | ↓ | ↑ |
| ↓Threshold (looser) | ↑ | ↓ | ↑ | ↓ |
Memory trick: SnNout (Sensitive test, Negative result rules OUT disease) | SpPin (Specific test, Positive result rules IN disease)